PPBT net incomeFY2025-$26.39M
PPBT net income was -$26.39M for fiscal 2025 (ended Dec 31, 2025), compared with -$7.24M in fiscal 2024.
Purple Biotech Ltd. (PPBT) financials
For fiscal 2025 (ended Dec 31, 2025), Purple Biotech Ltd. reported -$26.39M of net income.
- Net income, FY2025
- -$26.39M
- Free cash flow, FY2025
- -$5.66M
- EPS, diluted, FY2025
- $0.03
- Cash
- $8.72M
- Market cap
- $2.2M
FY2017FY2020
FY2016FY2025
FY2016FY2025
PPBT revenue and earnings growth
PPBT EPSFY2025$0.03
PPBT diluted EPS was $0.03 for fiscal 2025 (ended Dec 31, 2025).
PPBT free cash flowFY2025-$5.66M
PPBT free cash flow was -$5.66M for fiscal 2025 (ended Dec 31, 2025).
Income statement
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | $1.00M | $1.00M | $1.00M | $100.0K | - |
| Research and development | $3.73M | $7.62M | $17.03M | $16.32M | $11.83M | $7.24M | $2.28M | $5.27M | $4.64M | $4.18M |
| Selling, general and admin | $3.25M | $3.18M | $5.24M | $6.28M | $6.11M | $6.00M | $4.39M | $5.20M | $6.40M | $3.00M |
| Operating income | - | - | -$22.27M | -$22.60M | -$17.93M | -$12.61M | -$7.16M | -$7.83M | -$11.97M | -$7.18M |
| Interest expense | $982.0K | $483.0K | $2.19M | $67.0K | -$212.0K | $61.0K | $181.0K | $576.0K | $26.0K | $61.0K |
| Income tax | - | - | - | - | - | - | $216.0K | - | - | - |
| Net income | -$26.39M | -$7.24M | -$19.88M | -$21.67M | $18.38M | $28.00M | $5.85M | $5.20M | $12.18M | $12.13M |
| EPS, basic | $0.03 | $4.44 | $17.96 | $23.97 | $17568036.00 | - | - | - | - | - |
| EPS, diluted | $0.03 | $4.99 | $17.96 | $23.97 | $17568036.00 | - | - | - | - | - |
| Diluted shares | 480,053 | 1.6M | 1.1M | 904,054 | 17.6M | 11.5M | 19.4M | 14.2M | 9.5M | 5.8M |
Balance sheet
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $8.72M | $7.40M | $14.49M | $15.03M | $10.89M | $11.25M | $4.38M | $5.16M | $3.95M | $6.76M |
| Current assets | $9.87M | $8.91M | $15.79M | $33.26M | $48.47M | $59.28M | $8.30M | $8.51M | $7.98M | $14.90M |
| Total assets | $17.57M | $37.04M | $44.30M | $54.62M | $70.20M | $83.80M | $14.72M | $14.72M | $14.18M | $14.91M |
| Current liabilities | $7.75M | $3.99M | $9.70M | $7.06M | $4.25M | $3.10M | $3.55M | $3.31M | $3.97M | $1.27M |
| Total liabilities | $7.91M | $4.13M | $10.01M | $7.52M | $5.09M | $4.05M | $3.86M | $3.72M | $5.50M | $1.53M |
| Shareholders' equity | $9.71M | $32.86M | $34.30M | $47.10M | $65.11M | $79.75M | $10.86M | $11.00M | $8.69M | $13.38M |
Cash flow
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$5.66M | -$14.37M | -$19.93M | -$16.73M | -$374.0K | $1.71M | -$1.97M | -$8.48M | -$8.63M | -$6.26M |
| Capital expenditures | $3.0K | - | $3.0K | $26.0K | $115.0K | $156.0K | $11.0K | $16.0K | $13.0K | $10.0K |
| Free cash flow | -$5.66M | - | -$19.93M | -$16.76M | -$489.0K | $1.55M | -$1.98M | -$8.50M | -$8.64M | -$6.27M |
| Investing cash flow | $632.0K | $509.0K | $13.88M | $19.91M | $13.41M | -$49.59M | -$449.0K | $2.04M | $2.77M | -$7.77M |
| Financing cash flow | $6.33M | $6.77M | $5.45M | $1.11M | - | $68.49M | $5.23M | $7.79M | $3.00M | $10.29M |
| Stock-based compensation | $309.0K | $582.0K | $1.88M | $2.41M | $2.08M | $2.65M | $657.0K | $773.0K | $2.31M | $400.0K |
Key ratios
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth, YoY | - | - | - | - | - | 0.0% | 0.0% | 900.0% | - | - |
| Net income growth, YoY | - | - | - | - | -34.3% | 378.6% | 12.5% | -57.3% | 0.4% | 188.6% |
| EPS growth, YoY | - | - | -25.1% | - | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | -1261.2% | -715.6% | -782.6% | -11966.0% | - |
| Net margin | - | - | - | - | - | 2799.9% | 585.0% | 520.0% | 12177.0% | - |
| Free cash flow margin | - | - | - | - | - | 154.9% | -197.9% | -849.6% | -8640.0% | - |
| Return on equity | -271.6% | -22.0% | -58.0% | -46.0% | 28.2% | 35.1% | 53.9% | 47.3% | 140.2% | 90.6% |
| Return on assets | -150.2% | -19.5% | -44.9% | -39.7% | 26.2% | 33.4% | 39.7% | 35.3% | 85.9% | 81.3% |
| Current ratio | 1.27 | 2.23 | 1.63 | 4.71 | 11.41 | 19.14 | 2.34 | 2.57 | 2.01 | 11.70 |
Source: XBRL data Purple Biotech Ltd. files with the SEC, latest filing dated Mar 19, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
Per-share figures are as filed. The filings show no stock split in these periods.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
Foreign private issuers file annual reports with the SEC, so there are no quarterly statements here.
PPBT peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| PPBT | - | - | -$26.39M | - | $2.2M |
| LLY | $86.46B | +45.5% | $27.58B | 31.9% | $1.33T |
| JNJ | $99.33B | +7.8% | $16.09B | 16.2% | $679.13B |
| ABBV | $66.01B | +10.7% | $10.34B | 15.7% | $518.44B |
| MRK | $67.38B | +4.9% | $2.45B | 3.6% | $366.73B |
| NVS | $54.53B | +8.4% | $13.98B | 25.6% | $312.35B |
| AZN | $58.74B | +8.6% | $10.22B | 17.4% | $293.69B |
| ABT | $48.23B | +10.0% | $4.70B | 9.7% | $191.40B |
| NVO | DKK 309.06B | +6.4% | DKK 102.43B | 33.1% | $183.23B |
PPBT FAQ
6 questionsIs PPBT profitable?
No. Purple Biotech Ltd. reported a net loss of $26.39M for fiscal 2025 (ended Dec 31, 2025).How much cash and debt does PPBT have?
Purple Biotech Ltd. reported $8.72M in cash and cash equivalents on its most recent balance sheet in SEC filings.What is PPBT free cash flow?
Purple Biotech Ltd. generated -$5.66M of free cash flow for fiscal 2025 (ended Dec 31, 2025), which is operating cash flow of -$5.66M less capital expenditures.What is PPBT earnings per share?
Diluted earnings per share were $0.03 for fiscal 2025 (ended Dec 31, 2025), from SEC filings, restated for any stock split those filings show.When did PPBT last report financial results?
The latest statements here come from Purple Biotech Ltd.'s 20-F filed on Mar 19, 2026, covering the period ended Dec 31, 2025.Where does this PPBT financial data come from?
Quantisnow builds these statements from the structured XBRL data Purple Biotech Ltd. files with the SEC. It is provided for information only and is not investment advice.